Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?

@article{Mascolo2019AngiotensinIA,
  title={Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?},
  author={Annamaria Mascolo and Konrad Urbanek and Antonella De Angelis and Maurizio Sessa and Cristina Scavone and Liberato Berrino and Giuseppe Massimo Claudio Rosano and Annalisa Capuano and Francesco Rossi},
  journal={Heart Failure Reviews},
  year={2019},
  volume={25},
  pages={367-380}
}
Atrial fibrillation (AF) is a significant cause of morbidity and mortality as well as a public health burden considering the high costs of AF-related hospitalizations. Pre-clinical and clinical evidence showed a potential role of the renin angiotensin system (RAS) in the etiopathogenesis of AF. Among RAS mediators, angiotensin II (AII) and angiotensin 1–7 (A1–7) have been mostly investigated in AF. Specifically, the stimulation of the pathway mediated by AII or the inhibition of the pathway… Expand
News on angiotensin II and atrial fibrillation : from the molecular to the pathophysiological.
Introduction: atrial fibrillation is the most prevalent arrhythmia in the world, having high morbidity and mortality rates. Numerous studies have shown the involvement of the angiotensin renin systemExpand
The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19
TLDR
The available evidence on the role of RAAS in the heart and lung is discussed, summarizing all clinical data related to the use of drugs acting either by blocking the classic RAAS or stimulating the non-classic RAAS. Expand
Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation
TLDR
It is suggested that physicians select ACEIs/ARBs as an anti-AF therapy for patients with heart failure due to their additional benefits and for patients who have suffered AF, ACEIs /ARBs may be a routine drug for secondary prevention. Expand
The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?
TLDR
This review focuses on the involvement of tRAS in the progression of the mentioned diseases from an interdisciplinary clinical perspective and highlights therapeutic strategies that might be of major clinical importance in the future. Expand
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?
TLDR
It is concluded that neither ARBs nor ACEIs treatment will cause any side effects or undesirable interactions in COVID-19 infected hypertensive patients, and several studies have demonstrated no detrimental effects of RAS modulators on clinical severity, hospital/intensive care unit stay, ventilation and mortality. Expand
Attenuation of atrial remodeling by aliskiren via affecting oxidative stress, inflammation and PI3K/Akt signaling pathway
TLDR
ALS may offer cardioprotection in RAP-induced atrial remodeling, which may partly be ascribed to its anti-inflammatory and anti-oxidative stress action and the regulation of PI3K/Akt signaling pathway. Expand
Role of the Renin–Angiotensin–Aldosterone and Kinin–Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID
  • Samantha L Cooper, E. Boyle, +7 authors J. Woolard
  • Medicine
  • International journal of molecular sciences
  • 2021
TLDR
The impact of COVID-19 on the cardiovascular system, the mechanisms by which dysregulation of the RAAS and KKS can occur following virus infection and the future implications for pharmacological therapies are reviewed. Expand
Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials
TLDR
A meta-analysis found that SGLT2i use is associated with a 19.33% lower SAEs of AF/AFL compared with the placebo, and dapagliflozin users had the lowest SAE's of AF-AFL incidence. Expand
Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
TLDR
RAS may play a role in SARS-COV-2-induced cardiac and pulmonary damage, and pharmacological strategies that interfere with the viral attachment to ACE2 or that modulate the RAS are in clinical development for COVID-19. Expand
Cardiac arrhythmias in patients with COVID‐19
TLDR
Cardiac arrhythmias in patients with COVID‐19 is focused on, its underlying mechanisms, and proposed preventive and therapeutic strategies, and several antimicrobials that are currently used as potential therapeutic agents have uncertain benefit and yet may induce electrocardiographic QT prolongation with potential ventricular pro‐arrhythmic effects. Expand
...
1
2
...

References

SHOWING 1-10 OF 135 REFERENCES
The Role Of Renin Angiotensin System In Atrial Fibrillation.
TLDR
RAS antagonism has proven to be effective for primary and secondary prevention of AF in subjects with heart failure and left ventricular (LV) dysfunction, and in the absence of concomitant antiarrhythmic therapy, was not shown to reduce post cardioversion AF recurrences. Expand
The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.
TLDR
It is premature to recommend the use of ACE-Is and ARBs specifically for the prevention of AF, but as these drugs are safe and manageable, they should be considered the drugs of choice in patients with AF and coexisting clinical conditions such as hypertension, coronary disease, heart failure and diabetes mellitus. Expand
Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM.
TLDR
Evidence is provided that ANGI use may be beneficial in some patient subgroups with AF and underscores the need for randomized clinical trials defining more fully the role of angiotensin II inhibition in treating AF. Expand
Renin–angiotensin–aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy
TLDR
In patients with HCM, lower risk of new AF is observed in patients treated with either ACEIs or ARBs compared with those receiving neither of these medications, and remains consistent after propensity score adjustment. Expand
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).
TLDR
The need for randomized clinical trials to clearly define the role of RAS inhibitors in treating AF is underscored, as blocking the RAS did not provide additional benefit against AF recurrence in CTAF patients treated with an antiarrhythmic drug. Expand
The role of the renin-angiotensin system in the development of cardiovascular disease.
  • T. Unger
  • Medicine
  • The American journal of cardiology
  • 2002
TLDR
The combination of an AT(1) receptor antagonist with an ACE inhibitor represents an appealing therapeutic strategy, because it should produce more complete blockade of the RAS, while preserving the beneficial effects mediated by AT(2) receptor stimulation and increased bradykinin levels. Expand
Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues
TLDR
The findings suggest that the RAS should be considered to have a central role in the pathogenesis of different cardiovascular diseases, for both therapeutic and preventive purposes, without having to measure its level of activation in each patient. Expand
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.
TLDR
Ramipril is effective in preventing relapses of lone atrial fibrillation (LAF) in patients with arterial hypertension or several forms of heart disease in the absence of hypertension and/or heart disease. Expand
The Impact of Suppressing the Renin‐Angiotensin System on Atrial Fibrillation
TLDR
Heterogeneity hypothesis‐generating data suggest that inhibitors of the renin‐angiotensin system may provide benefit across the spectrum of atrial fibrillation. Expand
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
TLDR
Both ACEIs and ARBs appear to be effective in the prevention of atrial fibrillation, but this benefit appears to be limited to patients with systolic left ventricular dysfunction or LV hypertrophy. Expand
...
1
2
3
4
5
...